E88.3
Tumor lysis syndrome
Clinical Classification Guidelines
Use Additional Code
- code for adverse effect, if applicable, to identify drug (T45.1X5)
Inclusion Terms
- Tumor lysis syndrome (spontaneous)
- Tumor lysis syndrome following antineoplastic drug chemotherapy
Medical Intelligence & Overview
Tumor lysis syndrome (TLS) is a potentially serious condition that occurs when cancer cells break apart rapidly, releasing their contents into the bloodstream. This sudden release can lead to metabolic disturbances and, if not managed properly, may cause severe health complications. TLS is most commonly associated with certain types of cancer treatments but can also happen spontaneously. Recognizing the symptoms and understanding the causes can help in managing this condition effectively.
Causes & Symptoms
Clinical Causes: Rapid destruction of cancer cells during chemotherapy or radiation therapy, especially in cancers with high cell turnover such as leukemia and lymphoma. Spontaneous tumor lysis, which occurs without treatment, typically in aggressive or rapidly growing tumors. Use of medications that kill cancer cells or cause cell death quickly, increasing the risk of cell breakdown. Pre-existing high tumor burden, which increases the likelihood of cell lysis when treatment begins.
Key Symptoms: Swelling or discomfort due to kidney problems Nausea, vomiting, or diarrhea Muscle weakness or cramps Ekg changes or irregular heartbeat Increased urination or abnormal kidney function Confusion or decreased consciousness in severe cases
Diagnostic & Treatment
Diagnosis Path: Diagnosis of tumor lysis syndrome involves a combination of blood tests and physical assessments. Key diagnostic steps include:
Treatment Protocols: Managing tumor lysis syndrome focuses on preventing or treating metabolic disturbances and supporting organ function. Common approaches include:
Clinical Advice & FAQs
Billing Guidance
Is E88.3 a billable ICD-10 code?
Yes, E88.3 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report E88.3?
Clinical documentation must specify the nature of Tumor lysis syndrome and any associated comorbidities for accurate reporting.
Cite this Clinical Reference